TL;DR
Preparing a medical device for FDA clearance is not something that begins when the submission is written. It starts much earlier, with device classification, intended use, regulatory strategy, design controls, risk management, verification and validation, and a manufacturing process capable of producing the device consistently.
The strongest programs treat FDA readiness as part of product development from the beginning. That means understanding the regulatory pathway early, defining requirements that can actually be verified, generating objective evidence as the design matures, and maintaining documentation that tells a clear and traceable story.
For medical device companies, the goal is not simply to assemble a successful submission. It is to develop a product, quality system, and manufacturing strategy that can withstand regulatory review and support commercialization after clearance.
FDA Clearance Starts Long Before the Submission
One of the most common misconceptions in medical device development is that FDA clearance is primarily a regulatory documentation exercise. A company develops its product, completes testing, and then turns to regulatory specialists to assemble the submission.
In practice, many of the decisions that determine whether a submission will be straightforward or difficult are made months, and sometimes years, before the submission reaches FDA.
The intended use influences classification. Classification influences the regulatory pathway. The regulatory pathway influences testing requirements. Testing requirements affect design inputs, material selection, software development, packaging, sterilization, manufacturing processes, and ultimately the amount of evidence a company must generate.
FDA describes medical devices as falling into Class I, II, or III based on risk and the regulatory controls necessary to provide reasonable assurance of safety and effectiveness. Depending on the device, the route to market may involve exemption from premarket notification, a 510(k), a De Novo request, Premarket Approval, or another applicable pathway. FDA’s overview of device pathways provides the regulatory framework manufacturers should consider early in development.
This is why regulatory strategy should not be treated as the final stage of product development. It should help shape the development plan itself.
At Pathway MedTech, we support medical device companies across product development, quality, regulatory strategy, verification and validation, and manufacturing. Connecting these disciplines early can help identify regulatory or technical issues before they become expensive redesigns later in the program.
1. Define Intended Use and Classify the Device Early
Before deciding what testing to perform or what documentation to prepare, a company needs to understand exactly what device it intends to bring to market.
That sounds obvious, but the language surrounding intended use and indications can have significant regulatory consequences.
Who will use the device? What clinical problem does it address? In what environment will it be used? What patient population is involved? Does it contact the body? Is it implanted? Does it provide diagnostic information? Does it contain software? Is it sterile? Does it sustain or support life?
These characteristics help determine how FDA regulates the product.
Classification should therefore be one of the earliest regulatory activities in the development program. Teams should investigate the FDA Product Classification Database, applicable regulation numbers, product codes, device-specific guidance documents, recognized consensus standards, and previously cleared or authorized devices.
For many Class II devices, this analysis leads toward a 510(k). FDA states that a 510(k) generally requires demonstrating that the new device is substantially equivalent to a legally marketed predicate device. Substantial equivalence considers intended use, technological characteristics, and supporting performance information. Importantly, a new device does not have to be identical to its predicate. Differences, however, must be appropriately evaluated and supported. FDA explains the substantial equivalence framework here.
Novel low-to-moderate risk devices without a legally marketed predicate may instead be candidates for the De Novo pathway. Higher-risk Class III devices generally require Premarket Approval.
A common mistake is selecting a regulatory pathway based primarily on what appears fastest. The better question is which pathway is defensible based on the device’s intended use, risk profile, technology, and existing regulatory landscape.
Choosing incorrectly can affect far more than the submission. It can lead to unnecessary testing, missed testing, inappropriate predicate selection, design changes, additional FDA interaction, and significant delays.
Pathway supports clients in evaluating device classification and developing regulatory strategies that connect the regulatory pathway to the actual development work ahead.
2. Build the Regulatory Strategy Into Development
Once the likely pathway is understood, the next step is turning regulatory requirements into an executable development plan.
A regulatory strategy should answer more than, “Are we filing a 510(k)?”
It should establish what evidence will likely be needed to support the device.
Depending on the product, that evidence may include mechanical or functional bench testing, electrical safety, electromagnetic compatibility, software verification and validation, cybersecurity documentation, biocompatibility, usability or human factors engineering, sterilization validation, packaging validation, shelf-life studies, animal testing, clinical evidence, or other device-specific testing.
Not every device requires every category of evidence. The important point is that these requirements should be identified before the development team reaches design freeze.
For example, a patient-contacting device may require a biological evaluation based on the nature and duration of contact. FDA’s guidance on the use of ISO 10993-1 emphasizes a risk-based approach to biological evaluation rather than treating biocompatibility as a generic checklist of tests.
Similarly, a sterile device introduces additional questions involving sterilization modality, material compatibility, sterile barrier integrity, packaging validation, and shelf life. An electrically powered device may introduce IEC-based electrical safety and EMC considerations. Connected devices may introduce cybersecurity requirements that affect architecture and software development long before verification testing begins.
When these requirements are discovered late, teams can find themselves redesigning products that they believed were finished.
A stronger approach works backward from the anticipated regulatory evidence and incorporates those needs into design inputs, engineering decisions, supplier selection, manufacturing planning, and the verification strategy.
This is one reason Pathway uses a structured five-phase medical device development process. Regulatory, engineering, quality, and manufacturing considerations become progressively more defined as the product advances, rather than being addressed independently at the end.
3. Establish Design Controls and Traceability
A successful submission is built on evidence. That evidence becomes much easier to defend when the development program itself is controlled and traceable.
Medical device teams should establish a structured design and development framework appropriate to the device’s classification, complexity, and risk. This includes clearly documented user needs, design inputs, design outputs, risk management activities, design reviews, verification, validation, and design changes.
The objective is not documentation for documentation’s sake. Design controls create a logical chain between what the device is supposed to do and the evidence showing that it actually does it.
A requirement should be specific enough to verify. Verification should demonstrate that the corresponding requirement was met. Risk controls should connect identified hazards to design or process mitigations. Changes should be evaluated for their potential impact on requirements, risk, testing, manufacturing, and regulatory documentation.
Weak traceability often exposes problems that go deeper than paperwork.
A vague design input can lead to an ambiguous test method. An ambiguous test method can produce results that are difficult to interpret. A late design change can invalidate previous verification. A manufacturing change can affect device performance or introduce new risks.
These relationships become increasingly important as the program moves toward formal verification and regulatory submission.
The regulatory landscape has also evolved. FDA’s Quality Management System Regulation, or QMSR, became effective on February 2, 2026. The revised 21 CFR Part 820 incorporates ISO 13485:2016 by reference and further harmonizes FDA’s quality system requirements with internationally recognized medical device quality management principles.
For companies approaching FDA clearance today, quality system readiness should therefore develop alongside the product itself, not after regulatory authorization.
4. Treat Risk Management as a Development Tool
Risk management should not be a document that gets completed shortly before submission.
It should influence the product.
As the device architecture develops, teams should systematically identify foreseeable hazards, hazardous situations, potential harms, and the controls necessary to reduce associated risks. Those controls may influence the physical design, software architecture, labeling, manufacturing processes, packaging, usability, alarms, protective features, or instructions for use.
This creates an important connection between risk management and verification.
If a design feature exists to mitigate a meaningful risk, the development team should be able to demonstrate that the control works as intended. Risk management therefore helps identify what needs to be tested and why.
This is particularly important when new information appears during development. A design change, supplier change, test failure, usability finding, or manufacturing issue may alter the risk profile and require the team to revisit previous assumptions.
When risk management is performed continuously, these changes can be evaluated systematically. When it is performed retrospectively, teams often discover gaps at precisely the wrong time, when formal testing is underway or the submission is being assembled.
The strongest medical device programs use risk management as an engineering decision-making framework rather than simply a regulatory deliverable.
5. Design Verification Around the Regulatory Story
Verification answers a fundamental question: did we build the device according to its requirements?
For FDA-bound devices, the quality of that answer matters enormously.
Verification planning should begin well before testing. Teams need to define what will be tested, why it is being tested, which requirements are being evaluated, what methods will be used, how samples will be selected, and what constitutes an acceptable result.
Acceptance criteria should be established before results are known.
That distinction matters. Testing a product and then deciding whether the result is “good enough” is fundamentally different from defining objective acceptance criteria and demonstrating that the product meets them.
Another frequent mistake is performing formal verification on devices that do not adequately represent the intended production configuration. A prototype produced using development tooling, substitute materials, uncontrolled processes, or one-off assembly techniques may perform well, but the resulting evidence may not adequately represent the commercial device.
This is where regulatory readiness and manufacturing readiness begin to converge.
Pathway supports regulated Device Verification builds in an ISO 13485-certified environment, including DFM optimization, supplier qualification, controlled execution, and documentation structured to support regulatory submission and early commercialization.
The objective is not simply to manufacture test articles. It is to ensure that the articles being tested, and the processes used to build them, support the broader regulatory and commercialization strategy.
6. Do Not Confuse Verification With Validation
Verification and validation are closely related, but they answer different questions.
Verification asks whether the design outputs satisfy the design inputs.
Validation asks whether the finished device meets user needs and intended uses under actual or simulated conditions of use.
A device can technically meet every engineering specification and still fail to satisfy the needs of the people expected to use it.
That distinction becomes particularly important for devices where user interaction can influence safety or performance. Human factors, usability, labeling, workflow, ergonomics, environmental conditions, and foreseeable misuse may all affect the validation strategy.
Validation planning should therefore begin with a clear understanding of users, use environments, intended use, and critical tasks.
Teams that postpone this thinking may discover late in development that a technically functional product does not adequately address real-world use conditions.
Verification and validation should ultimately form part of a coherent evidence package. The specifications, test protocols, results, risk controls, and intended use should reinforce one another rather than exist as disconnected documentation.
7. Address Manufacturing Readiness Before Clearance
FDA clearance and manufacturing readiness are different milestones, but treating them as separate programs can create serious commercialization problems.
A company can invest heavily in developing and testing a device only to discover that its commercial manufacturing process cannot reliably reproduce what was submitted.
This is why Design for Manufacturability should occur before the device is considered finished.
Materials, tolerances, joining methods, component availability, inspection criteria, tooling, supplier capabilities, assembly sequences, process controls, packaging, sterilization, and operator variability can all influence the final device.
Manufacturing changes made late in development can also have regulatory consequences. A material substitution, new supplier, revised geometry, modified process, or packaging change may require additional risk analysis or testing depending on its potential effect on safety and performance.
The practical question is not simply, “Can we build the device?”
It is, “Can the intended manufacturing system build the same conforming device repeatedly, under controlled conditions, with objective evidence that the process is working as intended?”
Pathway’s integrated model is designed around this transition from prototype to manufacturing. Engineering, DFM, supply chain development, verification builds, quality systems, packaging, regulatory support, and manufacturing are considered as connected elements of the same commercialization process.
That integration can be especially valuable for early-stage companies that do not yet have extensive internal manufacturing or quality infrastructure.
8. Build Packaging, Sterilization, and Shelf Life Into the Plan
For sterile and packaged medical devices, the product submitted to FDA is more than the device sitting on an engineering bench.
The packaging system, sterilization process, labeling, and claimed shelf life can all become part of the evidence supporting the finished product.
Packaging therefore should not be treated as a final purchasing exercise.
Material selection, sterile barrier design, seal parameters, packaging equipment, sterilization compatibility, transportation stresses, accelerated aging, real-time aging, and package integrity can require significant development and validation work.
Changes to packaging can also affect sterilization performance, product protection, usability, labeling, and shelf-life claims.
The same principle applies to sterilization. Selecting EO, gamma, e-beam, or another modality can affect materials, product performance, packaging, residuals, processing parameters, lead times, and validation strategy.
These decisions are much easier to manage when they occur early enough to influence product development.
For teams approaching verification, packaging and sterilization timelines should be incorporated into the overall regulatory schedule. Otherwise, the device itself may be ready while the complete commercial configuration is not.
Pathway supports product and packaging validation as part of its broader regulatory and quality capabilities and coordinates activities necessary to prepare devices for commercialization.
9. Use FDA Interaction Strategically When Questions Matter
Not every regulatory question needs to be answered internally.
FDA’s Q-Submission Program provides mechanisms for companies to request feedback before an intended medical device submission. A Pre-Submission can be particularly useful when FDA feedback could materially influence development or submission preparation.
According to FDA’s May 2025 Q-Submission guidance, Pre-Submissions can address specific questions related to areas such as bench testing, biocompatibility, cybersecurity, clinical study design, and other issues relevant to an anticipated 510(k), De Novo request, PMA, or other device submission.
The value of FDA interaction is not simply receiving an answer. It is reducing uncertainty before substantial resources are committed.
Consider a company planning an expensive verification program around a novel technology. If there is meaningful uncertainty about the proposed test strategy, predicate, clinical evidence, or acceptance criteria, receiving FDA feedback before executing the program may be significantly more valuable than discovering disagreement after testing has been completed.
That does not mean every device needs a Pre-Submission.
The decision should be strategic. Teams should identify the specific regulatory uncertainties capable of changing the development plan and determine whether formal FDA feedback could meaningfully reduce that risk.
A well-prepared Q-Submission is therefore less about asking FDA, “What should we do?” and more about presenting a reasoned approach and asking focused questions about the areas where regulatory alignment matters most.
10. Assemble the Submission as a Coherent Technical Story
By the time submission preparation begins, most of the substantive work should already exist. The challenge becomes organizing that evidence into a clear regulatory argument. For a 510(k), that means demonstrating substantial equivalence to an appropriate predicate through intended use, technological characteristics, and supporting performance data. For a De Novo request, the submission must support the proposed classification and demonstrate that applicable controls can provide reasonable assurance of safety and effectiveness. PMA submissions carry a substantially higher evidentiary burden.
FDA now requires most 510(k) submissions to use the electronic Submission Template and Resource, or eSTAR, and De Novo requests are also subject to electronic submission requirements in many cases. The standardized format helps structure submissions, but a template cannot compensate for weak underlying evidence. The submission should tell a consistent story. The device description should agree with the drawings, the indications should align with the testing, risk controls should be reflected in the design, verification results should trace to requirements, biocompatibility should reflect actual patient-contacting materials and exposure, and sterilization and packaging evidence should represent the intended commercial configuration.
Contradictions create questions, and questions during review can become requests for additional information, additional testing, or delays. Strong submission preparation is therefore less about producing a large volume of documentation and more about making the technical and regulatory logic easy for a reviewer to follow. Pathway supports FDA submission preparation alongside the engineering, verification, quality, and manufacturing activities that generate the underlying evidence, helping maintain continuity between what was designed, what was tested, what was documented, and what will ultimately be manufactured.
11. Prepare for FDA Questions Before You Submit
Submission is not the end of the process. FDA may communicate with the applicant during review through interactive review, requests for clarification, or formal requests for additional information. Companies should anticipate this possibility before submission and ensure the people, documentation, and technical resources necessary to respond remain available.
A useful internal exercise is to review the submission from the perspective of an FDA reviewer. Where are the assumptions? Which technological differences require the most explanation? Are acceptance criteria justified? Are sample sizes defensible? Are there discrepancies between drawings, test reports, labeling, risk documentation, and the device description? Could a reviewer understand why each major test was performed and how the evidence supports the claims being made? This type of challenge review can identify weaknesses while the development team still has time to address them.
Teams should also avoid mentally disbanding the project immediately after submission. Engineers, regulatory specialists, quality personnel, testing partners, and suppliers may need to help answer questions during review. Preparing for that interaction can make the difference between a focused response and weeks spent reconstructing decisions that should already be documented.
FDA Clearance Is a Milestone, Not the Finish Line
FDA clearance or authorization is a major accomplishment, but it is not the end of medical device development. The company still has to manufacture the device consistently, maintain its quality system, manage suppliers, control changes, monitor production, maintain records, address complaints and postmarket obligations, and determine whether future changes affect the regulatory status of the product.
This is why the strongest FDA preparation strategies begin with commercialization in mind. The goal should not be to create one perfect batch of devices that passes testing. The goal should be to establish a controlled system capable of producing the intended device repeatedly and supporting it throughout its commercial life. Regulatory strategy, product development, risk management, verification and validation, quality systems, packaging, and manufacturing are not separate hurdles on the road to market. They are interconnected parts of the same process.
Pathway MedTech works with medical device companies across these transition points, from early regulatory and development strategy through verification, FDA submission support, manufacturing setup, packaging, sterilization coordination, and ongoing production. A recent Pathway case study illustrates this model, following a medical device startup from regulatory strategy and verification through successful 510(k) clearance and commercial manufacturing. When these functions are aligned early, teams are better positioned not only to reach FDA clearance, but to build a product that is genuinely ready for market.
